ACRSAclaris Therapeutics, Inc.
$3.75+66% 1Y
$3.75
$2.1352 weeks$6.54
Is the price fair?
What ACRS's price assumes
Aclaris Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 92.0× revenue.
92.0
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 6.07
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 6.07
- EV / EBIToperating margin −1050%: the multiple describes the denominator
- not meaningful
- Market capitalisation147.2 million shares, counted Jul 31, 2026
- $552M
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.